| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $157,733,257 | 57 | 100 |
| Bhatia Sangeeta N. | director | 0 | $0 | 2 | $267,746 | $-267,746 |
| Liu Joy | EVP and Chief Legal Officer | 0 | $0 | 4 | $1.77M | $-1.77M |
| Ambrose Kristen | SVP & Chief Accounting Officer | 0 | $0 | 5 | $1.98M | $-1.98M |
| Bunnage Mark E. | EVP, Chief Scientific Officer | 0 | $0 | 5 | $3M | $-3M |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 0 | $0 | 5 | $3.6M | $-3.6M |
| Biller Jonathan | EVP and Chief Legal Officer | 0 | $0 | 6 | $3.8M | $-3.8M |
| McKechnie Duncan | EVP, Chief Commercial Officer | 0 | $0 | 4 | $5.66M | $-5.66M |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 0 | $0 | 8 | $6.51M | $-6.51M |
| WAGNER CHARLES F JR | EVP, CO & FO | 0 | $0 | 2 | $10.78M | $-10.78M |
| Bozic Carmen | EVP and CMO | 0 | $0 | 10 | $11.31M | $-11.31M |
| Kewalramani Reshma | CEO & President | 0 | $0 | 1 | $19.74M | $-19.74M |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 0 | $0 | 2 | $28.38M | $-28.38M |
| LEIDEN JEFFREY M | Executive Chairman | 0 | $0 | 3 | $60.94M | $-60.94M |
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond …
Over the last 12 months, insiders at Vertex Pharmaceuticals Incorporated have bought $0 and sold $157.73M worth of Vertex Pharmaceuticals Incorporated stock.
On average, over the past 5 years, insiders at Vertex Pharmaceuticals Incorporated have bought $5.84M and sold $82.81M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $1.95M was made by SACHS BRUCE I (director) on 2025‑08‑06.
| 2026-07-02 | Sale | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 1,500 0.0006% | $524.99 | $787,485 | -2.50% | |
| 2026-07-02 | Sale | McKechnie Duncan | EVP, Chief Commercial Officer | 1,541 0.0006% | $519.00 | $799,779 | -2.50% | |
| 2026-07-01 | Sale | Liu Joy | EVP and Chief Legal Officer | 828 0.0003% | $502.71 | $416,244 | +3.41% | |
| 2026-06-26 | Sale | Bozic Carmen | EVP and CMO | 596 0.0002% | $482.50 | $287,570 | +4.74% | |
| 2026-06-18 | Sale | Bozic Carmen | EVP and CMO | 1,020 0.0004% | $462.17 | $471,413 | +13.65% | |
| 2026-06-15 | Sale | Bozic Carmen | EVP and CMO | 4,062 0.0016% | $450.00 | $1.83M | +13.31% | |
| 2026-06-05 | Sale | Bozic Carmen | EVP and CMO | 1,745 0.0007% | $450.00 | $785,250 | +13.62% | |
| 2026-05-29 | Sale | Bozic Carmen | EVP and CMO | 1,974 0.0008% | $450.00 | $888,300 | +13.01% | |
| 2026-05-15 | Sale | Bozic Carmen | EVP and CMO | 1,354 0.0006% | $453.45 | $613,971 | +15.07% | |
| 2026-05-15 | Sale | Bunnage Mark E. | EVP, Chief Scientific Officer | 33 <0.0001% | $453.45 | $14,964 | +15.07% | |
| 2026-05-12 | Sale | Bozic Carmen | EVP and CMO | 6,988 0.0028% | $450.00 | $3.14M | +11.97% | |
| 2026-05-04 | Sale | Bhatia Sangeeta N. | director | 318 0.0001% | $423.73 | $134,746 | +15.97% | |
| 2026-05-01 | Sale | Liu Joy | EVP and Chief Legal Officer | 1,104 0.0004% | $425.02 | $469,222 | +17.58% | |
| 2026-04-01 | Sale | Liu Joy | EVP and Chief Legal Officer | 978 0.0004% | $449.17 | $439,288 | +8.49% | |
| 2026-03-27 | Sale | Bozic Carmen | EVP and CMO | 2,329 0.001% | $450.95 | $1.05M | +11.86% | |
| 2026-03-13 | Sale | Bozic Carmen | EVP and CMO | 2,329 0.0009% | $481.79 | $1.12M | +2.35% | |
| 2026-03-11 | Sale | McKechnie Duncan | EVP, Chief Commercial Officer | 2,633 0.001% | $498.42 | $1.31M | -2.47% | |
| 2026-03-04 | Sale | McKechnie Duncan | EVP, Chief Commercial Officer | 2,437 0.001% | $475.30 | $1.16M | +0.48% | |
| 2026-03-02 | Sale | Liu Joy | EVP and Chief Legal Officer | 892 0.0004% | $495.96 | $442,396 | -1.45% | |
| 2026-02-27 | Sale | Kewalramani Reshma | CEO & President | 40,000 0.0156% | $493.47 | $19.74M | -3.47% |
| Kewalramani Reshma | CEO & President | 98278 0.0388% | $52.16M | 2 | 28 | +17.83% |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 55570 0.0219% | $29.49M | 1 | 105 | +5.21% |
| LEIDEN JEFFREY M | Executive Chairman | 24026 0.0095% | $12.75M | 2 | 55 | <0.0001% |
| Vertex Pharmaceuticals (Europe) Ltd | 10 percent owner | 5380940 2.123% | $2.86B | 4 | 0 | +14.31% |
| BOGER KENNETH S | SVP & Chief Legal Officer | 112999 0.0446% | $59.98M | 1 | 19 | +11.42% |
| Graves Kurt | EVP, Chief Commercial Officer | 59880 0.0236% | $31.78M | 1 | 11 | +4.03% |
| SACHS BRUCE I | director | 45000 0.0178% | $23.88M | 8 | 33 | +20.06% |
| SANDERS CHARLES A | director | 26383 0.0104% | $14M | 1 | 14 | +17.73% |
| WINGER DENNIS L | director | 6500 0.0026% | $3.45M | 1 | 0 | <0.0001% |
| ULLIAN ELAINE | director | 5265 0.0021% | $2.79M | 3 | 15 | +46.27% |
| MCGLYNN MARGARET G | 1099 0.0004% | $583,305.24 | 1 | 12 | +64.37% | |
| Slater Eve Elizabeth | director | 1105 0.0004% | $586,489.80 | 2 | 1 | +1.76% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$2,449,191,716 | 58 | 16.50% | $100.2B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 889 | +55.22% | 13M | +5.58% |
| Decreased Positions | 695 | -43.17% | 13M | -5.5% |
| New Positions | 251 | New | 3M | New |
| Sold Out Positions | 106 | Sold Out | 2M | Sold Out |
| Total Postitions | 1,804 | +12.05% | 236M | +0.09% |
| Capital World Investors | $11.71M | 10.2% | 25.91M | -3M | -9.82% | 2025-09-30 |
| Vanguard Group Inc | $10.95M | 9.53% | 24.22M | +243,088 | +1.01% | 2025-09-30 |
| Blackrock, Inc. | $10.06M | 8.76% | 22.25M | +381,102 | +1.74% | 2025-09-30 |
| Capital Research Global Investors | $7.48M | 6.52% | 16.55M | +444,990 | +2.76% | 2025-09-30 |
| State Street Corp | $5.25M | 4.57% | 11.61M | -169,227 | -1.44% | 2025-09-30 |
| Jpmorgan Chase & Co | $2.91M | 2.53% | 6.43M | +565,417 | +9.63% | 2025-09-30 |
| Geode Capital Management, Llc | $2.7M | 2.35% | 5.97M | +44,998 | +0.76% | 2025-09-30 |
| Wellington Management Group Llp | $2.16M | 1.88% | 4.77M | -41,344 | -0.86% | 2025-09-30 |
| Capital International Investors | $2.12M | 1.85% | 4.69M | +2M | +77.89% | 2025-09-30 |
| Alliancebernstein L.P. | $2.04M | 1.78% | 4.52M | +144,266 | +3.29% | 2025-09-30 |